MA54248A - Régulation de métaux traces pendant la production d'anticorps anti-cd38 - Google Patents

Régulation de métaux traces pendant la production d'anticorps anti-cd38

Info

Publication number
MA54248A
MA54248A MA054248A MA54248A MA54248A MA 54248 A MA54248 A MA 54248A MA 054248 A MA054248 A MA 054248A MA 54248 A MA54248 A MA 54248A MA 54248 A MA54248 A MA 54248A
Authority
MA
Morocco
Prior art keywords
regulation
antibody production
trace metals
during anti
metals during
Prior art date
Application number
MA054248A
Other languages
English (en)
Inventor
Nicole Larmore
Balasubramanian Ramanathan
Richard Yeager
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70551717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA54248(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA54248A publication Critical patent/MA54248A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054248A 2018-11-13 2019-11-13 Régulation de métaux traces pendant la production d'anticorps anti-cd38 MA54248A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862760782P 2018-11-13 2018-11-13

Publications (1)

Publication Number Publication Date
MA54248A true MA54248A (fr) 2021-09-22

Family

ID=70551717

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054248A MA54248A (fr) 2018-11-13 2019-11-13 Régulation de métaux traces pendant la production d'anticorps anti-cd38

Country Status (15)

Country Link
US (1) US11634499B2 (fr)
EP (2) EP4461310A3 (fr)
JP (2) JP7599418B2 (fr)
KR (1) KR20210091763A (fr)
CN (1) CN113015805B (fr)
AU (1) AU2019379858B2 (fr)
CA (1) CA3117447C (fr)
EA (1) EA202191352A1 (fr)
ES (1) ES2994759T3 (fr)
IL (1) IL282970A (fr)
MA (1) MA54248A (fr)
MX (1) MX2021005611A (fr)
SG (1) SG11202104092UA (fr)
TW (1) TW202039849A (fr)
WO (1) WO2020100073A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
JP6802791B2 (ja) 2014-12-04 2020-12-23 ヤンセン バイオテツク，インコーポレーテツド 急性骨髄性白血病の治療のための抗ｃｄ３８抗体
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
MD3827845T2 (ro) * 2015-11-03 2022-09-30 Janssen Biotech Inc Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
MA54248A (fr) 2018-11-13 2021-09-22 Janssen Biotech Inc Régulation de métaux traces pendant la production d'anticorps anti-cd38

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072565A (en) 1974-11-04 1978-02-07 The Dow Chemical Company Production of viruses in tissue culture without use of serum
DE3271210D1 (en) 1981-12-24 1986-06-19 Asahi Chemical Ind Method for the cultivation of normal diploid cells and cultivation medium used therefor
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
FR2543158B1 (fr) 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
AU2004218354B2 (en) 2003-03-05 2009-10-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
PT1623019E (pt) 2003-05-15 2010-07-20 Wyeth Llc ALIMENTAÆO COM GLUCOSE DE MODO LIMITADO PARA CULTURA DE CéLULAS ANIMAIS
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP3312196B1 (fr) 2005-03-23 2019-07-17 Genmab A/S Anticorps dirigés contre cd38 pour le traitement du myélome multiple
KR20150139636A (ko) 2005-10-12 2015-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
CA2633306A1 (fr) 2006-01-04 2007-07-12 Baxter International Inc. Milieux de culture cellulaire depourvus d'oligopeptides
DK3255141T3 (da) 2006-07-13 2022-01-31 Wyeth Llc Fremstilling af antistoffer med forbedret glycosyleringsmønster
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
EP2702077A2 (fr) * 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
SG11201600067YA (en) * 2013-07-23 2016-02-26 Biocon Ltd Methods for controlling fucosylation levels in proteins
US20150139988A1 (en) * 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
RU2712562C2 (ru) * 2014-02-27 2020-01-29 Ф.Хоффманн-Ля Рош Аг Модулирование клеточного роста и гликозилирования при производстве рекомбинантных гликопротеинов
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
KR101660580B1 (ko) * 2014-04-02 2016-09-28 프레스티지 바이오파마 피티이. 엘티디. 항체의 당 함량 조절을 통한 항체의 제조 방법
SG11201608080RA (en) * 2014-04-17 2016-10-28 Boehringer Ingelheim Rcv Gmbh Recombinant host cell for expressing proteins of interest
SI3227454T1 (sl) 2014-12-01 2020-06-30 Amgen Inc. Postopek za manipuliranje ravni vsebnosti glikana glikoproteina
EP3072957B1 (fr) * 2015-03-23 2019-07-10 Lonza Ltd Procédés permettant de réguler la glycosylation de protéines
WO2016196621A1 (fr) 2015-06-01 2016-12-08 Biogen Ma Inc. Supplémentation en manganèse pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
MD3827845T2 (ro) 2015-11-03 2022-09-30 Janssen Biotech Inc Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
MA54248A (fr) 2018-11-13 2021-09-22 Janssen Biotech Inc Régulation de métaux traces pendant la production d'anticorps anti-cd38

Also Published As

Publication number Publication date
EP4461310A3 (fr) 2025-03-12
MX2021005611A (es) 2021-06-30
WO2020100073A1 (fr) 2020-05-22
BR112021008879A2 (pt) 2021-10-26
IL282970A (en) 2021-06-30
ES2994759T3 (en) 2025-01-30
CA3117447A1 (fr) 2020-05-22
CA3117447C (fr) 2024-06-04
TW202039849A (zh) 2020-11-01
EP3880824A4 (fr) 2022-08-10
JP2022513018A (ja) 2022-02-07
CN113015805A (zh) 2021-06-22
AU2019379858A1 (en) 2021-05-20
US20200148782A1 (en) 2020-05-14
EP3880824A1 (fr) 2021-09-22
EA202191352A1 (ru) 2021-08-11
JP2024129019A (ja) 2024-09-26
EP3880824B1 (fr) 2024-07-24
CN113015805B (zh) 2024-12-03
KR20210091763A (ko) 2021-07-22
SG11202104092UA (en) 2021-05-28
JP7599418B2 (ja) 2024-12-13
EP4461310A2 (fr) 2024-11-13
US11634499B2 (en) 2023-04-25
AU2019379858B2 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
MA54248A (fr) Régulation de métaux traces pendant la production d'anticorps anti-cd38
EP3677589A4 (fr) Procédé amélioré de production d'un conjugué anticorps-médicament
EP3679011A4 (fr) Composés amide et nitrile et procédés de production et d'utilisation de ceux-ci
EP3677568A4 (fr) Nouveau procédé de production d'un conjugué anticorps-médicament
EP3709973A4 (fr) Procédés de production d'exosomes dérivés de csm
EP3693373A4 (fr) Procédé pour la production stéréosélective d'un dérivé de pyridone polycyclique substitué
MA50169A (fr) Procédé de production d'un électrocatalyseur
EP3749769A4 (fr) Procédés de production d'alcaloïdes de type morphinane et de dérivés
EP3368238A4 (fr) Procédés de fabrication d'atomisation de poudre métallique
EP3822000A4 (fr) Poudre d'alliage et son procédé de production
EP3604513A4 (fr) Composition pour la production de tagatose et procédé de production de tagatose l'utilisant
MA50859A (fr) Procédé pour la production d'une composition de lymphocytes t
EP3411476A4 (fr) Production améliorée d'immunoglobulines
EP3897717A4 (fr) Procédés de production d'anticorps hétérodimères
EP3397602A4 (fr) Procédé d'oxydation pour la production de thiosulfate de potassium
EP3734268A4 (fr) Procédé simplifié de quantification d'anticorps monoclonaux
EP3473361A4 (fr) Procédé de production de poudre métallique et poudre métallique
EP3459659A4 (fr) Poudre d'alliage et procédé de préparation associé
EP3647316A4 (fr) Procédé de production d'édulcorant à base d'allulose
EP3838451A4 (fr) Procédé de production de poudre métallique atomisée à l'eau
EP3712194A4 (fr) Procédé de production de polyamide avec addition régulée d'activateur, et polyamide ainsi produit
EP3901123A4 (fr) Procédé de production de fluoro-éthane et procédé de production d'une fluoro-oléfine
EP3802893A4 (fr) Procédés de production de poudres métalliques fines à partir de composés métalliques
EP3947409A4 (fr) Production biosynthétique d'udp-rhamnose
MA71753A (fr) Nouveaux procédés et intermédiaires pour la préparation de stimulateurs de guanylate cyclase soluble